NanoViricides (NYSE-A:NNVC) said on Tuesday that its business remains unaffected by US government tariffs, retaliatory trade policies, or federal spending cuts.
In a statement, the clinical-stage biotech firm highlighted to shareholders that it develops antiviral treatments, not vaccines, and sees growing demand for broad-spectrum antiviral drugs under the policy direction of US Health and Human Services Secretary Robert Kennedy.
NanoViricides highlighted its lead candidate, NV-387, as a potential treatment for measles, a disease with no approved therapy.
The company pointed to the rapid spread of measles in West Texas and other states, citing concerns over limited vaccine effectiveness and a possible drift in the virus toward vaccine escape.
NV-387, which mimics cellular structures to block viral entry, has shown efficacy in animal models against respiratory syncytial virus (RSV), influenza—including bird flu strains like H5N1—and COVID-19. The company is also preparing a Phase II trial application to test NV-387 for treating MPox in Central Africa, where an epidemic has persisted since mid-2024.
Beyond NV-387, NanoViricides is developing NV-HHV-1 for herpesvirus infections, including shingles and cold sores, and NV-HIV-1 for potential combination therapy in HIV/AIDS treatment.
Despite a recent drop in its stock price amid broader market weakness, NanoViricides said it sees strong long-term growth potential.
"With all of these developments in progress, we are not exposed to current macroeconomic factors such as wars, tariffs, export taxes, or spending cuts," said NanoViricides president Anil Diwan.
"We believe NV-387 has a bright future, and we are strategizing to bring this future closer to reality every day."
Shares of NanoViricides had gained 4.3% in early trading Tuesday.